A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02096471

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:37:03.214032+00:00

Published At

2019-01-10T00:00:00+00:00

Record Updated At

2019-01-10

Results Posted At

2019-01-10

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2019-01-10"

protocolSection.identificationModule.nctId

"NCT02096471"

protocolSection.identificationModule.officialTitle

"A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2019-01-10"

Study condition terms

• Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.